A case of palmoplantar pustular psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus

Int J Rheum Dis. 2022 Oct;25(10):1200-1202. doi: 10.1111/1756-185X.14392. Epub 2022 Aug 3.

Abstract

Palmoplantar pustular psoriasis (PPP) is a rare clinical form of psoriasis. It is usually seen on the palms and soles, and affects patients' quality of life. In most cases, topical or systemic treatments are not sufficiently effective, so management of PPP is generally difficult. Hydroxychloroquine (HQ) is an antimalarial drug that is widely used in many autoimmune rheumatic diseases, mainly in systemic lupus erythematosus (SLE). Several reports describe the induction and exacerbation of psoriasis by HQ. Within this report, we aimed to put emphasis on considering possible drug effects by presenting a case of PPP, induced by HQ.

Keywords: Hydroxychloroquine; palmoplantar pustular psoriasis; systemic lupus erythematosus.

Publication types

  • Case Reports

MeSH terms

  • Antimalarials* / adverse effects
  • Humans
  • Hydroxychloroquine / adverse effects
  • Lupus Erythematosus, Systemic* / chemically induced
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / drug therapy
  • Psoriasis* / chemically induced
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy
  • Quality of Life

Substances

  • Antimalarials
  • Hydroxychloroquine